Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Min-Jeong | - |
dc.contributor.author | Yeo, Seung-Gu | - |
dc.contributor.author | Kim, Eun Seok | - |
dc.contributor.author | Min, Chul Kee | - |
dc.contributor.author | Sean, Pyung | - |
dc.date.accessioned | 2021-08-12T01:18:50Z | - |
dc.date.available | 2021-08-12T01:18:50Z | - |
dc.date.issued | 2013-03 | - |
dc.identifier.issn | 1792-1074 | - |
dc.identifier.issn | 1792-1082 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13862 | - |
dc.description.abstract | This study aimed to investigate the clinical outcomes of intensity-modulated radiotherapy (IMRT)-based stereotactic body radiotherapy (SBRT) for patients with stage I non-small cell lung cancer (NSCLC). A prospective database of 16 consecutive patients receiving SBRT for pathologically-proven and peripherally-located stage I NSCLC was reviewed. Fifteen patients were medically inoperable and one patient refused to undergo surgery. The median age of the patients was 76 years (range, 69-86). Treatment planning used four-dimensional computed tomography and fixed-field IMRT (n=11) or volumetric-modulated arc therapy (V MAT; n=5). The SBRT scheme was 48 Gy in four fractions (n=9) or 55 Gy in five fractions (n=7), delivered on consecutive days. The overall response rate at 6 months was 78.6%, including a complete response in three (21.4%) patients and a partial response in eight (57.1%). Three patients (21.4%) demonstrated a stable disease status. The median follow-up time was 14 months (range, 6-20) for the surviving patients. One patient developed local failure at 11 months, while another suffered from regional failure in a subcarinal lymph node at 4 months. Two patients did not survive within the first 6 months; one patient died during salvage chemotherapy for mediastinal lymph node metastasis and the other succumbed to a cause unrelated to lung cancer. The Kaplan-Meier estimates of local failure-free, progression-free and overall survival rates at 18 months were 91.0, 85.2 and 87.5%, respectively. The toxicity was mild; no severe (grade >= 3) toxicity was identified. IMRT-based (including VMAT) delivery of SBRT for patients with stage I NSCLC demonstrated favorable responses and local control without severe toxicity. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Spandidos Publications | - |
dc.title | Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer | - |
dc.type | Article | - |
dc.publisher.location | 그리이스 | - |
dc.identifier.doi | 10.3892/ol.2012.1082 | - |
dc.identifier.scopusid | 2-s2.0-84872723275 | - |
dc.identifier.wosid | 000315423900021 | - |
dc.identifier.bibliographicCitation | Oncology Letters, v.5, no.3, pp 840 - 844 | - |
dc.citation.title | Oncology Letters | - |
dc.citation.volume | 5 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 840 | - |
dc.citation.endPage | 844 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | I/II | - |
dc.subject.keywordAuthor | non-small cell lung cancer | - |
dc.subject.keywordAuthor | medically inoperable | - |
dc.subject.keywordAuthor | stage I | - |
dc.subject.keywordAuthor | stereotactic body radiotherapy | - |
dc.subject.keywordAuthor | intensity-modulated radiotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.